Log in

NASDAQ:BBHVanEck Vectors Biotech ETF Stock Price, Forecast & News

-2.50 (-1.55 %)
(As of 08/11/2020 04:00 PM ET)
Today's Range
Now: $159.08
50-Day Range
MA: $166.91
52-Week Range
Now: $159.08
Volume51,071 shs
Average Volume29,617 shs
Market Capitalization$492.67 million
P/E RatioN/A
Dividend Yield0.28%

Geographic Exposure of BBH

Currency Exposure of BBH

Sector Exposure of BBH

Industry Exposure of BBH

Basic Details

Issuer Van Eck
Fund NameVanEck Vectors Biotech ETF
Tax ClassificationRegulated Investment Company
Inception Date12/20/2011
Fund ManagerHao-Hung Peter Liao, Guo Hua Jason Jin

Fund Focus

Asset ClassEquity
BenchmarkMarket Vectors US Listed Biotech 25 Index
FocusHealth Care
Development LevelDeveloped Markets

Fund Statistics

Assets Under Management$1.92 billion
Average Daily Volume$14,048.50

ETF Expenses

Management Fee0.35%
Other Expenses0.04%
Total Expenses0.39%
Fee Waiver-0.04%
Net Expenses0.35%

Administrator, Advisor and Custodian

AdministratorVan Eck Associates Corporation
AdvisorVan Eck Associates Corporation
CustodianThe Bank of New York Mellon Corporation
DistributorVan Eck Securities Corporation
Transfer AgentThe Bank of New York Mellon Corporation
Lead Market MakerVirtu Financial
-2.50 (-1.55 %)
(As of 08/11/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BBH News and Ratings via Email

Sign-up to receive the latest news and ratings for BBH and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

VanEck Vectors Biotech ETF (NASDAQ:BBH) Frequently Asked Questions

How has VanEck Vectors Biotech ETF's stock been impacted by COVID-19 (Coronavirus)?

VanEck Vectors Biotech ETF's stock was trading at $126.82 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BBH stock has increased by 25.4% and is now trading at $159.08.
View which stocks have been most impacted by Coronavirus

Has VanEck Vectors Biotech ETF been receiving favorable news coverage?

News headlines about BBH stock have been trending negative recently, InfoTrie reports. The research firm identifies positive and negative media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. VanEck Vectors Biotech ETF earned a news impact score of -2.6 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days.
View the latest news about VanEck Vectors Biotech ETF

Are investors shorting VanEck Vectors Biotech ETF?

VanEck Vectors Biotech ETF saw a increase in short interest in January. As of January 31st, there was short interest totaling 50,200 shares, an increase of 12.6% from the January 15th total of 44,600 shares. Based on an average trading volume of 14,700 shares, the days-to-cover ratio is currently 3.4 days.
View VanEck Vectors Biotech ETF's Short Interest

Who are some of VanEck Vectors Biotech ETF's key competitors?

What other stocks do shareholders of VanEck Vectors Biotech ETF own?

Based on aggregate information from My MarketBeat watchlists, some companies that other VanEck Vectors Biotech ETF investors own include Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Sanofi (SNY), Cidara Therapeutics (CDTX), Intel (INTC), (MRNA), Micron Technology (MU), Pfizer (PFE), Quest Diagnostics (DGX) and Novavax (NVAX).

What is VanEck Vectors Biotech ETF's stock symbol?

VanEck Vectors Biotech ETF trades on the NASDAQ under the ticker symbol "BBH."

Who are VanEck Vectors Biotech ETF's major shareholders?

VanEck Vectors Biotech ETF's stock is owned by many different retail and institutional investors. Top institutional investors include UBS Group AG (1.35%), Murphy Capital Management Inc. (1.10%), Envestnet Asset Management Inc. (0.62%), HighTower Advisors LLC (0.47%), Boston Research & Management Inc. (0.46%) and Raymond James & Associates (0.46%).

Which institutional investors are selling VanEck Vectors Biotech ETF stock?

BBH stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, Murphy Capital Management Inc., Aspiriant LLC, Boston Research & Management Inc., Telemus Capital LLC, and Tufton Capital Management.

Which institutional investors are buying VanEck Vectors Biotech ETF stock?

BBH stock was purchased by a variety of institutional investors in the last quarter, including LFA Lugano Financial Advisors SA, Envestnet Asset Management Inc., Wedbush Securities Inc., Columbus Macro LLC, Raymond James & Associates, Prudential PLC, Raymond James Financial Services Advisors Inc., and Cambridge Investment Research Advisors Inc..

How do I buy shares of VanEck Vectors Biotech ETF?

Shares of BBH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is VanEck Vectors Biotech ETF's stock price today?

One share of BBH stock can currently be purchased for approximately $159.08.

How big of a company is VanEck Vectors Biotech ETF?

VanEck Vectors Biotech ETF has a market capitalization of $492.67 million.

This page was last updated on 8/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.